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Abstract
Mexico, like many low- and middle-income countries (LMICs), faces an epidemic of chronic non-communicable 
diseases (NCDs), specifically diabetes, hypertension, obesity, and lipid disorders. Many people with these NCDs 
may not be aware that they have a disease, pointing to the need for broader screening programs. The traditional 
prevention policy in Mexico was based on screening with a paper-based risk factor questionnaire. However, 
this was used to screen patients already seeking healthcare services at facilities, and screening goals were set as 
a function of the number of questionnaires applied, not number of individuals screened. Due to this, Fundación 
Carlos Slim developed Medición Integrada para la Detección Oportuna (MIDOTM), or Integrated Measurement 
for Early Detection, an NCD screening and proactive prevention policy. 
This document is a policy analysis based on early learnings from the initial implementation of MIDO in eight 
primary healthcare centers in two central Mexican states. 
MIDO was found to expand screening programs beyond clinic walls, systematize community screening 
strategies, emphasize the detection of pre-disease phases, incorporate lifestyle counseling, and propose screening 
goals based on population targets. In collaboration with the Mexican Ministry of Health, MIDO has successfully 
screened over 500 000 individuals—about 40% of whom would not have been screened under previous policies. 
Of these more than 500 000 screened individuals, 13.4% had pre-diabetes (fasting glucose between 100 and 125 
mg/dL), and 5.8% had undiagnosed diabetes (defined as fasting glucose above 126 mg/dL or random glucose 
above 200 mg/dL). However, there is still room for improvement in linking positive results from screening with 
disease confirmation and with patient incorporation into disease management. The experience of implementing 
MIDO in Mexico suggests that primary and secondary prevention programs in other parts of the world 
should consider the need for population-based screening targets, a greater focus on pre-disease stages, and the 
streamlining of the transition between screening, confirmation of diagnosis, and incorporation of patients into 
the healthcare system.
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Global Situation
Diabetes affects at least 415 million people worldwide and 
in 2015 accounted for an estimated 12% of global health 
expenditures.1 Low- and middle-income countries (LMICs), 
with limited infrastructure for diabetes care, bear the burden 
of 75% of these cases.2
LMICs must, therefore, determine which prevention efforts 
are the most cost-effective for reverting this epidemic and 
where to allocate scarce resources to achieve maximum 
impact.3 Although policy recommendations on specific 
regulatory measures to encourage healthier diets enjoy broad 
consensus,1 prevention and screening programs in a clinical 
setting are not as well-defined.4
The Mexican Situation
Mexico is no exception to this global epidemic; confirmed 
cases of diabetes in adults over 20 years of age have been rising 
steadily from 4.0% in 1993, to 5.8% in 2000,5 7.0% in 2006,6 
and 9.2% in the most recent nationwide survey in 2012.7 
Other related chronic non-communicable diseases (NCDs)[1] 
have experienced similar increases, with the prevalence of 
obesity rising by almost 60%, and hypertension by almost 
30% between 1993 and 2012.8 
Moreover, confirmed cases may severely underestimate the 
epidemic: the true prevalence of diabetes was estimated to 
be 10.9% in 2000,9 and 14.4% in 2006.10 This suggests that 
approximately half of Mexicans with diabetes are unaware of 
their disease status, and therefore require broader screening 
programs to reach them.
Policy Context
Since 1999, Mexico’s Ministry of Health’s NCD screening 
policy has been using a paper risk factor questionnaire in 
adults above 20 years of age.11 However, this intervention 
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is limited—only passively screening established patients 
of a primary health center (PHC), and it operates without 
population-based screening goals or up-to-date robust 
information systems.12
In response to the growing NCD epidemic, in 2010 Fundación 
Carlos Slim (FCS) developed Medición Integrada para la 
Detección Oportuna (MIDOTM), or Integrated Measurement 
for Early Detection. MIDO is an innovative healthcare policy 
that incorporates proactive primary and secondary NCD 
efforts into PHCs[2]. 
MIDO is a core pillar of FCS’s CASALUDTM, a comprehensive 
healthcare model (that includes respective practical tools) 
for NCD prevention and disease management. The other 
pillars of CASALUD include patient-centered healthcare, 
monitoring of the medication supply chain, capacity building, 
and evidence-based disease management.8,14 
In 2013, the Mexican government launched the National 
Strategy for the Prevention and Control of Overweight, 
Obesity, and Diabetes (hereafter referred to as the “National 
Strategy”) in order to systematize prevention efforts for these 
diseases.15 MIDO was incorporated into the National Strategy 
as a reference policy for primary and secondary prevention 
in PHCs, especially in the practical implementation of 
screening tools and in the ongoing monitoring of screening 
progress and control over the epidemic. Due to FCS’ alliance 
with the Ministry of Health, MIDO currently operates, and 
complements the Ministry of Health’s NCD screening policy, 
in 138 PHCs in 27 states (out of Mexico’s 32) as part of the 
CASALUD Model. 
Likewise, FCS developed the NCD Integrated Dashboard 
to monitor the state of NCDs screened and treated under 
CASALUD. The Integrated Dashboard is a public, transparent 
website updated on a daily basis at the different health care 
levels (PHC, regional, state, and national). The Dashboard is 
an integral part of the Mexican NCD National Observatory 
that monitors the entire National Strategy[3], and allows 
authorities to make decisions based on robust, real-time data. 
Description of Integrated Measurement for Early Detection
MIDO is a screening and proactive prevention policy carried 
out through: all-in-one tools for outreach, screening, and 
counseling in PHCs and at a community level, and a robust 
information system to facilitate public health planning 
and patient follow-up. Importantly, MIDO is based on a 
proprietary and comprehensive framework of the patient 
engagement continuum, which is adopted by PHCs currently 
operating CASALUD. 
The patient engagement continuum is defined as a three-
step process that (1) provides patients with information 
about their health status (through screening), (2) confirms 
their diagnosis, and (3) incorporates them into PHCs. It 
is important to mention that MIDO is designed to operate 
exclusively within the primary care level, and does not 
contemplate patients with complications, who should be 
appropriately referred to secondary or tertiary care centers. 
MIDO’s entry point to this patient engagement continuum 
takes place through 2 different screening tools: the MIDO 
Mobile Cart for screening at PHCs, and the MIDO Backpack 
for screening at the community/household level. PHCs are 
fully autonomous in the use of these tools; they are responsible 
for establishing the schedule and personnel responsible for 
their operation in order to fulfill the population screening 
targets. Both screening tools include equipment to measure 
waist circumference, height, and weight, a body mass index 
calculator, blood pressure monitor, and a glucose testing kit[4]. 
All measurements are performed on all patients, with the 
exception of the glucose test, which is performed based on 
the results obtained from a risk factor questionnaire. 
MIDO’s screening questionnaire incorporates the algorithm 
defined by CENAPRECE, Mexico’s National Center of 
Preventive Programs and Disease Control, in order to 
determine diabetes risk to make decisions on glucose blood 
test screening. MIDO’s questionnaire also incorporates the 
most recent international evidence-based cardiovascular risk 
evaluation tools, and is validated in the Mexican context[5]. 
Importantly, MIDO incorporates pre-disease stages instead of 
merely dichotomizing screened individuals into “healthy” and 
“sick” categories. Specifically, pre-obesity is defined as body 
mass index between 25-29.9, pre-hypertension as systolic 
blood pressure between 130-139 mm Hg or diastolic pressure 
between 85-89 mm Hg, and pre-diabetes as fasting glucose 
between 100-125 mg/dL. Healthy individuals are those 
with values under these ranges, and those with a disease are 
defined as having values above these ranges. For diabetes, a 
probable case is defined as fasting glucose above 126 mg/dL or 
random glucose above 200 mg/dL. After obtaining the results, 
screened individuals receive personalized health promotion 
in the form of counseling and pamphlets that include step-
by-step instructions on lifestyle changes and time frames for 
repeat testing.
Both tools incorporate proprietary software, SI-MIDOTM, 
either on a computer for the Mobile Cart, or as an app for a 
tablet for the MIDO Backpack. Healthcare professionals enter 
the information of screened individuals into SI-MIDO, which 
facilitates follow-up by providing a database of the screened 
population and their results.
Additionally, in order to shift from paper-based records 
to nominal information systems, FCS worked with the 
Ministry of Health within the framework of the National 
Strategy to design, develop, and scale the Sistema Nominal 
de Información en Crónicas (SICTM) or NCD Information 
System. FCS is currently consolidating the SI-MIDO and SIC 
information systems, so that health providers and decision-
makers can identify those newly screened patients who were 
then incorporated into, and treated at a PHC.
Policy Questions and Data Collection for the Analysis of 
Integrated Measurement for Early Detection
This policy analysis is based on early learnings from the 
initial implementation of MIDO. The analysis is structured 
to answer 2 questions: Is MIDO offering solutions to improve 
screening efforts in PHCs? What policy lessons can be learned 
from MIDO’s initial implementation? The study was carried 
out in eight PHCs in 2 central Mexican states, using four 
instruments specifically designed to answer the 2 questions 
above mentioned:
•	 Interviews with high level public health authorities of 2 
states and directors of eight PHCs (68 interviews over the 
course of 2 years).
•	 Shadowing and interviews of 60 individuals screened 
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with the MIDO Mobile Cart.
•	 Analysis of 19 community screening events with the 
MIDO Backpack. 
•	 Analysis of the SI-MIDO database from the two studied 
states (over 35 000 screened individuals).
Additionally, the researchers obtained information from 
the Dashboard on screenings carried out nationwide (over 
500 000 individuals screened in the 27 states where MIDO 
operates). 
Findings of Integrated Measurement for Early Detection as 
a Screening and Proactive Prevention Policy 
Our findings from the policy analysis are organized along 
each step of the patient engagement continuum: population 
screening, confirmation of disease status, and incorporation 
of confirmed cases into PHCs. Findings are summarized in 
Table and then described in detail in this section. 
MIDO was found to yield positive results on the first phase 
of the continuum; specifically, MIDO expands screening 
programs beyond clinic walls, systematizes community 
screening strategies, emphasizes the detection of pre-disease 
phases, and establishes screening goals based on population 
targets. However, MIDO has yet to show results in the second 
and third phases of the patient engagement continuum: 
confirmation and incorporation.
Step of the Continuum: Screening
Policy issue addressed: Screening in Primary Health Centers 
Restricted to Current Patients
The previous Mexican screening strategy was engaged 
in prevention only passively, as it carried out screenings 
exclusively for patients already actively seeking care at PHCs. 
MIDO changes screening policies by going beyond the 
screening of symptomatic patients to include the screening of 
apparently healthy individuals. 
This distinction is not insignificant; of individuals screened 
with MIDO Mobile Cart, 17% were accompanying a patient 
and 23% were handling administrative or paperwork issues 
at the PHC. In other words, 40% of those screened would not 
have been screened in the absence of MIDO. 
MIDO broadens the scope of the population screened: as 
of December 5, 2016, a total of 548 355 individuals had 
been screened at the 138 PHCs that use MIDO, as per the 
Dashboard.16 Of this screened population, 13.4% of the 
individuals had pre-diabetes (fasting glucose between 100 
and 125 mg/dL), and 5.8% had undiagnosed diabetes (defined 
as glycated hemoglobin levels above 7%). These numbers 
show the importance of engaging the PHC health system in 
a discussion on the benefits of population-based screening 
strategies.
Policy Issue Addressed: Minimal Community Screening
In previous years, screening activities were primarily based 
out of PHCs. MIDO has shown that screening strategies can 
reach a larger population once they move beyond the walls of 
health care clinics, and that community screening and broad 
outreach strategies should be standardized, systematized, and 
incorporated into the public healthcare system. 
The MIDO Backpack allows PHCs to perform home 
visits and/or screening campaigns in community spaces, 
including community centers, schools, and private and public 
institutions. Five of the eight observed PHCs performed 
household visits or convened public events, in 2014 and 2015, 
leading to 1980 individual screenings. PHCs that performed 
screenings in the community and households had a more 
balanced ratio between women and men (67/33) than PHCs 
that only performed screening at PHCs (75/25). Screening in 
community spaces reduces barriers to accessing preventive 
screening services, and increases access for people (mainly 
men) who otherwise would not have interacted with the 
healthcare system.
Policy Issue Addressed: Emphasis on Disease
Prior to the National Strategy, Mexico’s screening policy 
focused on detecting existing diseases, thereby neglecting 
detection of pre-disease stages. In contrast, MIDO 
emphasizes the importance of screening for pre-disease 
stages and providing feedback (pamphlets with personalized 
action plans and lifestyle counseling) to individuals with 
pre-disease conditions. Because of MIDO, 13.4% of the 
screened population now knows that they have pre-diabetes 
(fasting glucose between 100 and 125 mg/dL). This segment 
of the screened population received a call to action through 
appropriate health promotion and lifestyle counseling to 
proactively prevent NCDs before they develop.
Policy Issue Addressed: Screening Goals Based on Number of 
Performed Screening Tests
The goal of the National Strategy and of MIDO is to screen 
100% of people above 20 years of age within the geographic 
boundaries of each PHC, therefore marking a shift away 
from traditional screening goals based on the number of tests 
performed. Screening metrics calculated with the proportion 
of individuals screened are essential, as under the traditional 
strategy, multiple tests could be performed on the same person. 
These screening targets based on the total adult population 
of specific geographical areas under the jurisdiction of a 
corresponding PHC promote PHC ownership over the 
screening activities. Each PHC is responsible for carrying out 
the appropriate screening activities to fulfill their population 
goal, which is publicly available in the Dashboard.
As of December 5, 2016, the Dashboard shows that 548 355 
people have been screened, representing 77.3% of the general 
goal for screening 709 811 individuals by the end of the 2016.16 
Steps of the Continuum: Confirmation and Incorporation
Policy Issue Yet to Be Improved: Complicated and Lengthy 
Process to Confirm Diagnosis
Despite the progress that MIDO has made in improving 
the first step of the patient engagement continuum, many 
PHCs continue to struggle with operational and bureaucratic 
barriers. These factors often prevent patients from reaching 
the next step in the engagement continuum: disease 
confirmation.
Once a screened individual is told they have a probable 
NCD, they must navigate complicated and time-consuming 
appointment scheduling and laboratory testing processes. 
From the sample of 60 shadowed MIDO users, none of the 
25 who were screened and detected with a probable NCD 
attempted (that day) to schedule a visit. Sixteen of these 
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Table. The Patient Engagement Continuum: Screening, Confirmation, and Incorporation
Step of the 
Continuum
Type of 
Prevention Policy Issue
Policy Solution Offered 
Through MIDO Specific Actions Offered Through MIDO Findings of Policy Analysis
Screening
Primary and 
secondary
Screening in PHCs 
restricted to current 
patients
Screen all individuals at PHCs, 
not just established patients
Screening with a MIDO Mobile Cart in PHCs including all 
individuals present at a PHC.
40% of those screened with MIDO would not have been screened 
without this policy.
Minimal community 
screening
Expand and systematize 
community screening strategies
Community screening with MIDO Backpack through 
home visits and at community spaces.
Community screenings reach a more balanced ratio of men to women 
(33/67) compared to PHC screening (25/75). 
Emphasis on disease Emphasize detecting pre-
disease stages, and prevention 
counseling
Identification of individuals at risk for developing NCDs 
(at pre-disease stages, conditions more amenable to 
prevention and lifestyle changes) and provision of 
personalized action plans and counseling.
MIDO places emphasis on pre-disease stages through personalized 
pamphlets and counseling. MIDO screening identified that 13.4% of 
screened individuals had pre-diabetes (fasting glucose between 100 and 
125 mg/dL), and 5.8% had undiagnosed diabetes (defined as glycated 
hemoglobin levels above 7%).
Screening goals based 
on number of performed 
screening tests
Set screening goals based on 
number of screened individuals 
and population targets
Establishment of screening goals as the percentage 
of screened individuals of the target population in a 
certain geographical area.
Each PHC has a clearly defined population of responsibility (population-
based goal), and progress is measured in a public and transparent 
manner through the Dashboard. As of December 5, 2016, 548 355 
people have been screened, 77.3% of the total goal for 2016.
Confirmation of 
diagnosis
Secondary
Complicated and lengthy 
process to confirm 
diagnosis
Design a lean process for 
confirmation of diagnosis 
(towards the design of a one-
stop shop)
MIDO proposes that screening, immediate referral to 
confirmation, and appointment scheduling happen at 
the same service touchpoint.
(Implementation in progress. Policy analysis limited to conceptual design 
of the tools.) Preliminary findings suggest that a very low proportion of 
patients schedule a confirmation appointment after their screening.
Incorporation into 
PHC and treatment
Precursor to 
tertiary
Screening efforts not 
linked to incorporation 
of patients into the 
healthcare system
Design a lean process for 
scheduling first appointment 
(towards the design of a one-
stop shop)
SI-MIDO and SIC will consolidate screening information 
so decision-makers can track newly screened patients 
(using SI-MIDO) and assure their incorporation into a 
PHC (SIC).
(Implementation in progress. Policy analysis limited to conceptual design 
of the tools.) PHCs do not currently keep track of screened patients and 
cannot quantify losses between each step of the continuum.
Abbreviations: MIDO, Medición Integrada para la Detección Oportuna; NCD, non-communicable disease; PHC, primary health center. 
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patients reported that it was because the process was too 
complicated and/or time-consuming, which is in line with the 
general opinion of health personnel.
These patients’ negative perceptions are understandable, as 
under current practices, after an initial screening it takes at 
least 2 visits to the physician’s office and one intermediate 
visit to an external laboratory to confirm an NCD diagnosis. 
MIDO supports the efforts of the National Strategy to create 
lean processes to convert the steps of the patient engagement 
continuum into a one-stop shop. Screening, immediate 
referral to a confirmation lab test, and the scheduling of an 
appointment with a physician should happen at the same 
point of service, as shown in Figure.
Policy Issue Yet to Be improved: Screening Efforts not Linked to 
Incorporation of Patients Into the Healthcare System
Once patients with a disease or pre-disease have their 
condition confirmed, they must attend their first medical 
or counseling appointment as a pre-requisite for disease 
management. However, PHCs do not currently keep records 
of newly-detected individuals, nor do they follow protocols to 
guarantee that these individuals make an appointment with a 
physician. As a result, the current proportion of patients that 
are lost-to-follow-up along the continuum is unknown and 
PHCs cannot currently identify which screened individuals 
obtain appointments. 
FCS is currently consolidating SI-MIDO and SIC to quantify 
losses between screening and treatment in order to analyze 
and strengthen the linkages between these activities. By using 
a unique universal identification number assigned to each 
person screened and incorporated into a PHC, decision-
makers will be able to track how many screened individuals 
are then treated.
Reflections on Improving Non-communicable Disease 
Proactive Prevention Policies 
The experience of MIDO suggests that other screening policies 
worldwide should not neglect three aspects of primary and 
secondary prevention:
•	 Screening programs should be measured with 
population-based targets in order to ensure full coverage 
and reach a high proportion of the population living 
with an undiagnosed disease (who may not have medical 
coverage). All members of a defined geographic area 
should be screened at least once, with subsequent follow-
up screenings according to risk levels. 
•	 A screening policy should contemplate the importance 
of confirming diagnoses and incorporating patients with 
a disease into health clinics. Primary and secondary 
prevention should be seen as a patient engagement 
continuum that links to tertiary prevention, and efforts 
should be invested in smoothing the transition and 
reducing losses between each step.
•	 It is important to not lose sight of what a screening policy 
should accomplish: the prevention of disease and related 
complications. Therefore, it is essential that screening 
policies not only focus on disease, but also on pre-disease 
stages. Lifestyle counseling for individuals with pre-
disease stages is especially important, as these pre-disease 
stages are more amenable to lifestyle changes.
As may be the case in other LMICs, the heterogeneous 
nature of PHCs and lack of standardized processes affect 
the entire patient engagement continuum. For example, the 
implementation of MIDO suffers from high rotation turnover 
rates in those responsible for its operation. Of 8 studied PHCs, 
7 had appointed a nursing student intern to operate the MIDO 
Mobile Cart and 1 had appointed a medical school intern. 
While some student interns were supervised or mentored by 
a senior nurse, others were not. This lack of standardization 
is reflected in the quality of screening: MIDO operators only 
explained results and provided feedback to four of the 25 
individuals with a probable disease. 
MIDO has strengths as a screening and proactive prevention 
policy to bridge the gap between the National Strategy and 
actionable prevention efforts in a clinical setting. However, 
there is still room for improvement in linking early detection 
Figure. Screening Process With MIDO.
Note: MIDO Control is also shown in this diagram. It is an auxiliary tertiary prevention strategy for patients with a previously diagnosed NCD 
to monitor their condition and screen for other NCDs. Abbreviations: MIDO, Medición Integrada para la Detección Oportuna; NCD, non-
communicable disease.
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with disease confirmation and patient incorporation into 
disease management.
The lessons learned from the initial implementation of this 
policy are valuable for any screening and prevention policy, 
especially one carried out in a LMIC.
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Endnotes
[1] MIDO focuses on specific chronic NCDs: diabetes, hypertension, obesity, 
chronic kidney disease, and lipid disorders. For the sake of simplicity, during this 
paper, “NCDs” will refer to these diseases listed here.
[2] In this document, “primary prevention” is used to refer to efforts to prevent 
the occurrence of a disease, “secondary prevention” to refer to efforts to detect 
or diagnose a disease before signs or symptoms are evident, and “tertiary 
prevention” to refer to efforts to reduce the impact of a diagnosed disease.13 
[3] Publicly available at: http://oment.uanl.mx/tablero-de-control-de-
enfermedades/.
[4] Lipid profiles can also be performed according to each PHCs’ needs and 
capacity. 
[5] The questionnaire includes questions on previous personal and family 
history of chronic NCDs as well as risk factors, such as smoking.
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